• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Retatrutide 2381089-83-2
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution

Wockhardt receives US FDA approval for Olopatadine HCI

financialexpressJuly 04, 2017

Tag: WOCKHARDT , FDA

Wockhardt has received final approval from US FDA for its ANDA for 0.1 per cent ophthalmic solution of Olopatadine HCI. The eye drop Olopatadine HCI 0.1 per cent ophthalmic solution is a generic version of Patanol, marketed at a US by Alcon, a subsidiary of Novartis

The product will be manufactured at US FDA approved contract manufacturing organisation based in Montreal, Canada.

Previous:Convergence of Blockchain with Emerging Technologies Set to Disrupt the Healthcare Industry by 2025

Next:Domino Printech India to launch Ax-Series

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Wockhardt receives US FDA approval for Olopatadine HCI | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

You may like
More>>

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0
Adriacin HCL (FDA)

Adriacin HCL (FDA)
4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）

4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
Ivermectin (FDA)

Ivermectin (FDA)
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Aciclovir (FDA)

Aciclovir (FDA)
Irinotecan (FDA)

Irinotecan (FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service